Cargando…

Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer

BACKGROUND: (99m)Technetium labeled methylene diphosphonate bone scans (BSs) are commonly used to monitor disease progression in bone for patients with metastatic breast cancer (MBC). However, new BS lesions may represent osteoblastic bone healing, which we now define as bone pseudoprogression. In t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Mingxi, Jin, Yizi, Yang, Ziyi, Hu, Xichun, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209838/ https://www.ncbi.nlm.nih.gov/pubmed/34188696 http://dx.doi.org/10.1177/17588359211022881

Ejemplares similares

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Development and validation of a nomogram for predicting overall survival of patients with cancer of unknown primary: a real-world data analysis
por: Jin, Yizi, et al.
Publicado: (2021)

Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
por: Zhang, Jian, et al.
Publicado: (2022)

Pseudoprogression after advanced first-line endocrine therapy in metastatic breast cancer with bone metastasis: A case report
por: Tian, Aijuan, et al.
Publicado: (2023)

A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
por: Zhao, Yannan, et al.
Publicado: (2017)

Multiple oligodendroglioma with pseudoprogression
por: Matsuyama, Junko
Publicado: (2012)

Pseudoprogression of brain tumors
por: Thust, Stefanie C., et al.
Publicado: (2018)

Pseudoprogression and Immunotherapy Phenomena
por: Waxman, Elizabeth S., et al.
Publicado: (2020)

A case of pseudoprogression in avelumab maintenance therapy for metastatic bladder cancer
por: Hayakawa, Nozomi, et al.
Publicado: (2022)

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
por: Lin, Ying, et al.
Publicado: (2020)

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy
por: Jia, Wenxiao, et al.
Publicado: (2019)

Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer
por: Sarma, Maithreyi, et al.
Publicado: (2020)

Identification of Key Genes Associated with Brain Metastasis from Breast Cancer: A Bioinformatics Analysis
por: Zeng, Cheng, et al.
Publicado: (2022)

The maximum standardized uptake value of (18) F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer
por: Zhang, Jian, et al.
Publicado: (2013)

Application of a Novel (68)Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients
por: Miao, Haitao, et al.
Publicado: (2022)

Efficacy of chemotherapy after hormone therapy for hormone receptor–positive metastatic breast cancer
por: Mori, Ryutaro, et al.
Publicado: (2014)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

Pseudoprogression in low-grade glioma
por: Slater, Jason M., et al.
Publicado: (2019)

Phase II study of Radium‐223 dichloride combined with hormonal therapy for hormone receptor‐positive, bone‐dominant metastatic breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2019)

Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China
por: Liu, Chang, et al.
Publicado: (2020)

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report
por: Wang, Junhui, et al.
Publicado: (2023)

Treatment Considerations for the Management of Patients With Hormone Receptor–Positive Metastatic Breast Cancer
por: Visovsky, Constance
Publicado: (2014)

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
por: Keenan, Tanya E., et al.
Publicado: (2021)

Pseudoprogression as an adverse event of glioblastoma therapy
por: Balaña, Carmen, et al.
Publicado: (2017)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
por: Ozaki, Yukinori, et al.
Publicado: (2017)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor–Positive Breast Cancer
por: Lee, Eunice Yoojin, et al.
Publicado: (2023)

Hormonal Receptor Status Determines Prognostic Significance of FGFR2 in Invasive Breast Carcinoma
por: Braun, Marcin, et al.
Publicado: (2020)

Delayed pseudoprogression of a vestibular schwannoma postradiosurgery
por: Malone, Janna, et al.
Publicado: (2020)

Pseudoprogression in lung cancer: a case report
por: Meoni, Giulia, et al.
Publicado: (2020)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment()()
por: Vander Jagt, Thomas A., et al.
Publicado: (2018)

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
por: Trabjerg, Natacha Dencker, et al.
Publicado: (2019)

Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer
por: Kim, Eun Young, et al.
Publicado: (2019)

Pseudoprogression or unexpected favorable response to third-line therapy: a challenging metastatic bladder cancer case
por: Soares, Adriana, et al.
Publicado: (2020)

Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration‐resistant prostate cancer
por: Kageyama, Takumi, et al.
Publicado: (2022)

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8mg1b5mrsmhclhvrkh5reogio4